March 27, 2017 / 11:10 AM / 4 months ago

BRIEF-Arqule trial did not meet its primary endpoint of progression free survival

1 Min Read

March 27 (Reuters) - Arqule Inc

* Trial did not meet its primary endpoint of progression free survival (pfs).

* There were no new safety issues observed in trial

* Its partner, Kyowa Hakko Kirin, announced top-line results of JET-HCC phase 3 trial of Tivantinib in Japan Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below